Sufang Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sufang Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jifei Chen
Acute Respiratory Infectious Diseases Network Laboratory, Department of Science and Education, GCP Institutional Office, Biobank of Guangxi Chest Hospital, Liuzhou, China
1 shared publication Liuyan Chen
State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, China
1 shared publicationShan Lu
Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publicationShuai Li
Key Laboratory of Biological Molecular Medicine Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China
1 shared publicationYanping Ning
Department of lmmunology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China
1 shared publicationYaobin Wang
Key Laboratory of Biological Molecular Medicine Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China
1 shared publication
Latest Publications
- Open Access
- 7 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Metabolic syndrome-related gene signature for prognosis and immune microenvironment prediction in hepatocellular carcinoma
Metabolic syndrome is a major risk factor for hepatocellular carcinoma (HCC) progression, yet the role of metabolic syndrome-related genes in HCC remains incompletely understood. Using bioinformatics approaches, we investigated the influence of these genes on HCC prognosis and tumor biology. Two distinct patient clusters (C1 and C2) were identified based on metabolic gene expression, with C2 exhibiting poorer survival, increased stemness, and higher risk scores. A risk model further revealed that high-risk patients had worse outcomes, elevated immunosuppressive cell infiltration, and distinct phenotypic features. Experimental validation via qRT-PCR confirmed upregulation of risk model genes (particularly KIAA1841 and TUBA1B) in HCC cell lines and patient blood samples. Notably, post-surgical declines in KIAA1841 and TUBA1B levels were observed. Our findings highlight the clinical relevance of metabolic syndrome-related genes in HCC, linking them to prognosis, tumor microenvironment remodeling, cancer stemness, and immunotherapy response.
- 7 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessMetabolic syndrome-related gene signature for prognosis and immune microenvironment prediction in hepatocellular carcinoma
Metabolic syndrome is a major risk factor for hepatocellular carcinoma (HCC) progression, yet the role of metabolic syndrome-related genes in HCC remains incompletely understood. Using bioinformatics approaches, we investigated the influence of these genes on HCC prognosis and tumor biology. Two distinct patient clusters (C1 and C2) were identified based on metabolic gene expression, with C2 exhibiting poorer survival, increased stemness, and higher risk scores. A risk model further revealed that high-risk patients had worse outcomes, elevated immunosuppressive cell infiltration, and distinct phenotypic features. Experimental validation via qRT-PCR confirmed upregulation of risk model genes (particularly KIAA1841 and TUBA1B) in HCC cell lines and patient blood samples. Notably, post-surgical declines in KIAA1841 and TUBA1B levels were observed. Our findings highlight the clinical relevance of metabolic syndrome-related genes in HCC, linking them to prognosis, tumor microenvironment remodeling, cancer stemness, and immunotherapy response.